About the Tumor Immunology Session
Tumor immunology explores the intricate relationship between cancer cells and the immune system. It delves into understanding how cancer cells evade immune detection and how the immune system can be harnessed to recognize and destroy tumors. Key areas of study include tumor antigens, immune checkpoint pathways, and immunotherapies. By identifying specific antigens expressed by tumors, researchers aim to develop targeted therapies that enhance immune recognition of cancer cells. Immune checkpoint inhibitors, such as PD-1 and CTLA-4 blockers, unleash the immune system's ability to attack tumors. Additionally, adoptive cell therapies, like CAR-T cells, genetically engineer immune cells to better recognize and kill cancer. Advancements in tumor immunology hold promise for more effective and personalized cancer treatments, offering hope for improved outcomes and quality of life for patients.
Topics Covered in Tumor Immunology
Tumor Antigens
Antigen Presentation
Cancer Immunoediting
Checkpoint Pathways
T-Cell Exhaustion
Myeloid Suppressor Cells
Related Scientific Sessions at CIOC 2027
Why Attend the Tumor Immunology Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Tumor Immunology work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Tumor Immunology research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Tumor Immunology track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Tumor Immunology Conference 2027 — FAQs
What is the Tumor Immunology track at CIOC 2027?
The Tumor Immunology track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Tumor Immunology. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Tumor Immunology sessions?
Cancer researchers and clinicians, educators and students with an interest in Tumor Immunology are all welcome — whether presenting or attending.
Can I present my research in the Tumor Immunology track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Tumor Immunology sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Tumor Immunology track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.